Jim Gabriele named president and CEO of M2GEN

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Jim Gabriele was named president and chief executive officer of M2GEN.

Gabriele is a data scientist who was most recently senior vice president and chief strategy & data science officer within the Medical Devices Sector at Johnson & Johnson.

M2GEN has linked clinical and genomic databases and runs one of the largest observational research studies in cancer, which tracks patients throughout their lifetime, links longitudinal clinical data with molecular information, and enables a deeper understanding of a patient’s disease.

As senior vice president and chief strategy & data Science officer at Johnson & Johnson, he led global strategy development, pricing strategy, data science, data strategy, digital customer experience and business insights. 

Prior to that, he held senior strategy and data science roles in the Johnson & Johnson Pharmaceutical organization. 

Gabriele succeeds Helge Bastian.

Table of Contents

YOU MAY BE INTERESTED IN

Physician-scientists by day, a funk-loving musical troupe by night. You may have seen The CheckPoints—a 13 member cover band with a three-piece brass section and Jim Allison on harmonica—movin’, groovin’, and gettin’ down as a mainstay closing act at ASCO, AACR, or the Society for Immunotherapy of Cancer annual meetings.
At the 2026 Annual Meeting of the American Society of Clinical Oncology in Chicago, results from the phase III HARMONi-6 trial were presented at the plenary session and published simultaneously in The Lancet. The HARMONi-6 trial tested a novel bispecific antibody that engages PD-1 and VEGF (ivonescimab), given with platinum-doublet chemotherapy to patients with previously untreated advanced squamous non-small cell lung cancer. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login